finanzwire.de

Search

MEVIS MEDICAL SOLUTIONS AG (FRA:M3V) DGAP-News: MeVis Medical Solutions AG: MeVis publishes figures for the third quarter of fiscal year 2017/2018

Transparency directive : regulatory news

21/08/2018 08:00

30/08/2018 15:51
21/08/2018 08:00
15/05/2018 15:00
20/02/2018 17:20
23/01/2018 14:30
11/01/2018 19:17
11/09/2017 12:14
22/08/2017 11:10
18/05/2017 16:30
06/03/2017 12:26

DGAP-News: MeVis Medical Solutions AG / Key word(s): Interim Report/9-month figures
MeVis Medical Solutions AG: MeVis publishes figures for the third quarter of fiscal year 2017/2018

21.08.2018 / 08:00
The issuer is solely responsible for the content of this announcement.


As expected, decline in sales also in the third quarter

  • Revenues at EUR 3.9 million approximately 12 % below previous year's level
  • EBIT of EUR 4.4 million in the first nine months (compared to EUR 5.3 million in the previous year)
  • EBIT margin stable at 37 % (previous year 38 %)
  • Profit after tax of EUR 5.1 million (compared to EUR 4.0 million in the previous year)

Bremen, August 21, 2018 - MeVis Medical Solutions AG [ISIN: DE000A0LBFE4], a leading provider of medical imaging software, announces the results for the first three quarters of fiscal year 2017/2018 (reporting period October 1, 2017 to June 30, 2018).

Sales in the third quarter of fiscal year 2017/2018 came to EUR 3,900 k, about 12 % below previous year (EUR 4,400 k). Licensing business declined by 28 % in the third quarter to EUR 995 k and maintenance business fell by 9 % to EUR 1,632 k. The service business slightly increased from EUR 1,256 k in the previous year period to EUR 1,270 k. Revenues thus amounted to EUR 12,133 k in the first nine months of the year (prev. year: EUR 14,196 k), of which EUR 8,192 k was attributable to the Digital Mammography segment (prev. year: EUR 8,984 k) and EUR 3,941 k to Other Diagnostics (prev. year: EUR 5,212 k). In the previous year, the revenues in the Other Diagnostics segment also included the one-off revenues of EUR 1,800 k from the sale of MeVisLab usage rights. At 68 % (prev. year: 72 %, without one-off revenue from sale of usage rights), the Digital Mammography segment continues to be the main source of revenues at the Company.

Thus, the EBIT (earnings before financial result and taxes) of EUR 1,304 k was generated in the third quarter and EUR 4,440 k in the first nine months of the year, compared to EUR 1,717 k and EUR 5,327 k in the previous year's periods. At 37 %, the EBIT margin for the first nine months remained largely stable compared to a previous year value of 38 %.

The financial result improved significantly in the period under review to EUR 685 k (prev. year:
EUR -211 k). In comparison to the previous year, there were significant changes in the balance of income and expenses from exchange rate differences of EUR 120 k (prev. year: EUR -502 k), as well as in the earnings of the 51 % share in MeVis BreastCare GmbH & Co. KG of EUR 461 k (prev. year: EUR 173 k), which is recognized at equity.

Earnings after taxes amounted to EUR 5,122 k (prev. year: EUR 3,967 k), which corresponds to undiluted earnings per share of EUR 2.81 (prev. year: EUR 2.18).

"As expected, sales in the third quarter of the current financial year were also down compared to the previous year, particularly in the mammography segment. However, good cost management allowed the EBIT margin to be maintained at an attractive level of 37 %. Encouragingly, the first sales from a joint project with Varex Imaging were realized in the past quarter, which will be continued in the coming months. This mainly involves cooperation on innovative software modules in the medical sector but also increasingly in the industrial sector," said Marcus Kirchhoff, CEO of Mevis Medical Solutions AG. Dr. Robert Hannemann, CFO of MeVis Medical Solutions AG added: "We therefore maintain our forecast for the current fiscal year and expect a significant decline in sales to between EUR 14.5 million and EUR 15.0 million and an EBIT between EUR 3.0 million and EUR 3.5 million."

The company's financial reports can be downloaded from the following website:
http://www.mevis.de/investor-relations/finanzberichte/



21.08.2018 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: MeVis Medical Solutions AG
Caroline-Herschel-Str. 1
28359 Bremen
Germany
Phone: +49 421 224 95 0
Fax: +49 421 224 95 999
E-mail: ir@mevis.de
Internet: http://www.mevis.de
ISIN: DE000A0LBFE4
WKN: A0LBFE
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Munich, Stuttgart, Tradegate Exchange

 
End of News DGAP News Service

715729  21.08.2018 

fncls.ssp?fn=show_t_gif&application_id=715729&application_name=news&site_id=symex